AstraZeneca (LON:AZN) Earns “Buy” Rating from Berenberg Bank

AstraZeneca (LON:AZNGet Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Berenberg Bank in a research report issued on Monday, Marketbeat reports. They currently have a GBX 140 ($1.74) price target on the biopharmaceutical company’s stock. Berenberg Bank’s target price would indicate a potential downside of 98.75% from the company’s previous close.

AZN has been the topic of a number of other reports. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a £140 ($174.19) target price on shares of AstraZeneca in a report on Friday, November 22nd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,935.67 ($98.74).

Get Our Latest Stock Analysis on AZN

AstraZeneca Price Performance

LON AZN opened at £111.70 ($138.98) on Monday. The firm’s 50 day moving average is £105.88 and its 200-day moving average is £115.38. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The company has a market capitalization of £173.13 billion, a PE ratio of 3,546.03, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12-month low of GBX 9,461 ($117.72) and a 12-month high of £133.88 ($166.58).

Insiders Place Their Bets

In other news, insider Pascal Soriot bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were bought at an average cost of £102.03 ($126.95) per share, for a total transaction of £2,040,600 ($2,539,007.09). Also, insider Tony Mok purchased 1,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were acquired at an average price of £126.80 ($157.77) per share, with a total value of £190,200 ($236,655.47). Company insiders own 0.04% of the company’s stock.

About AstraZeneca

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Recommended Stories

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.